NEW YORK (GenomeWeb News) — Whatman today said it will provide DNA collection kits based on its FTA elute technology to an international prostate cancer pharmacogenotyping study that aims to uncover links between SNPs and drug efficacy, side-effects, or individual susceptibility to prostate cancer.
.
The study is part of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy trial, also known as STAMPEDE.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.